Search

Displaying results 1351 - 1360 of 4598 in total
  1. Drug

    Cryptenamine

    go.drugbank.com/drugs/DB00785
    Approved

    It has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects.

  2. Drug

    Methaqualone

    go.drugbank.com/drugs/DB04833
    ApprovedIllicitWithdrawn

    The sedative-hypnotic activity was first noted by Indian researchers in the 1950s and in 1962 methaqualone itself was patented in the US by Wallace and Tiernan. … Clandestinely produced methaqualone is still seized by government agencies and police forces around the world.

  3. Drug

    N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine

    go.drugbank.com/drugs/DB14196
    Approved

    N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine is a component of black rubber. It is also a dermatological sensitizer and allergen. Sensitivity to N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine may be identified with a clinical patch test.

  4. Drug

    Gallium Ga-68 gozetotide

    go.drugbank.com/drugs/DB16019
    ApprovedInvestigational

    [L43542] In December of the same year, the drug was fully authorized by the EMA.[L44682] In Octer 2022, Ga-68 PSMA-11 was approved by Health Canada for diagnostic use in men with prostate cancer. … [L27006] On December 1, 2020, Ga-68 PSMA-11 was approved by the FDA as the first molecular-targeted drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)

  5. Drug

    Olutasidenib

    go.drugbank.com/drugs/DB16267
    ApprovedInvestigational

    Olutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022. … [L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test.

  6. Drug

    Rauwolfia serpentina root

    go.drugbank.com/drugs/DB09363
    Investigational

    This product was approved prior to Jan 1, 1982, but since, has been discontinued due to its propensity for leading to depression [L1616, L1630].

  7. Drug

    Sufentanil

    go.drugbank.com/drugs/DB00708
    ApprovedInvestigational

    It is administered by the intravenous, epidural and sublingual routes. … Consideration may be made in the future for the use of the sublingual form in the US military in cases where analgesia is required immediately [L4718].

  8. Drug

    ISS-1018

    go.drugbank.com/drugs/DB05463
    Investigational

    (TNF-alpha) by plasmacytoid dendritic cells (pDC). … ISS 1018 signals through Toll-like receptor 9 (TLR9) to induce the production of immunoglobulin by B cells and interferon (IFN) -alpha, IFN-beta, interleukin-12 (IL-12), and tumor necrosis factor - alpha

  9. Drug

    Albumin human

    go.drugbank.com/drugs/DB00062
    ApprovedInvestigational

    Also known as _Albuminex_ 5% or 25%, one brand of human serum albumin is prepared from the pooled plasma of US donors in FDA-licensed facilities in the US [F229]. … This is a biosimilar drug to existing human serum albumin and was approved for a biological license at both 5% and 25% concentrations by the FDA on June 21, 2018 [L3101].

    Products: SK Albumin 20% Injection
  10. Drug

    Choline magnesium trisalicylate

    go.drugbank.com/drugs/DB01401
    Approved

    Trisalicylate significantly reduces methotrexate renal clearance, displacing methotrexate from protein, increasing the fraction unbound by 28% [A19653, A19654].